Establishment of the anti-tumor immunotherapy using dendritic cells transfected with tumor extracted RNA
Establishment of the anti-tumor immunotherapy using dendritic cells transfected with tumor extracted RNA
批准号:
11671152
负责人:
OSADA Takuya
金额:
$2.24万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
1999
资助国家:
日本
项目状态:
已结题
起止时间:
1999 至 2000
中文摘要
在本研究中,有可能通过将从人结肠癌细胞系提取的mRNA导入人树突状细胞,并与T淋巴细胞在体外共培养来建立细胞毒性T淋巴细胞。结果表明,该CTL仅选择性地杀死从中提取导入RNA的细胞系。并且,当比较使用脂质体的情况和不使用脂质体的情况下的CTL诱导效率时,尽管对脂质体进行了评价,但由于其效率很低,因此没有观察到显著差异。虽然检查了从人手术标本中回收mRNA的效率,但如所估计的,屈服点在样品的固定情况下受到很大影响,并且mRNA通常也是片段化的。因此,将从这些固定样品中提取的RNA导入树突细胞似乎不是有效的。相反,冷冻样品似乎适合作为该方法的材料,因为mRNA在屈服点丰富,并且因为片段化也很少。基于本研究,显示了不仅从手术样品的大样本,而且从小样本如活组织切片中提取mRNA,可以制备呈递对患者肿瘤特异性的肿瘤抗原的树突状细胞疫苗。这些结果表明树突状细胞疗法的进一步适应性扩展。
英文摘要
In the present examination, it was possible to establish a cytotoxic T lymphocyte by introducing mRNA extracted from human colon cancer cell line into the human dendritic cell, and coculturing with T lymphocyte in in vitro. It was shown that this CTL selectively killed only the cell line from which the introduced RNA was extracted. And, the induction efficiency of CTL, when it was compared in the case in which Liposome was used and case in which it was not used, though it was evaluated of Liposome, as it is efficient a little, no significant difference could be observed. Though the efficiency of the mRNA recovery from the human surgery specimen was examined, the yield point was greatly influenced in fixation situation of samples as estimated, and mRNA was also generally fragmented. Therefore, it seemed not to be effective to introduce RNA extracted from these fixed specimen into dendritic cells. On the contrary, freezing samples seemed to be suitable as a material for this method, since mRNA was abounding on the yield point, and since the fragmentation was also little. Based on the present examination, it was shown that by extracting mRNA not only from large specimen of surgical sample but also from small samples such as the biopsy piece, it is possible to make dendritic cell vaccine which presented the tumor antigens specific to the patient's tumor. These results indicate further adaptation extension of the dendritic cell therapy.
期刊论文(56)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
Kitayama J, Osada T, et al: "E-selectin can mediate the arrest type of adhesion of colon cancer cells under physiological shear flow"European Joural of Caucer. 36. 121-127 (2000)
Kitayama J,Osada T,等人:“E-选择素可以介导生理剪切流下结肠癌细胞粘附的阻滞类型”European Joural of Caucer。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Nita ME, Tsuno N, et al.: "p21 Waf1/Cip1 expression is a prognostic marker in curative resected esophageal squamous cell carcinoma, but not p274Kip1, p53, or Rb."Ann Surg Oncol. 6. 481-8 (1999)
Nita ME、Tsuno N 等人:“p21 Waf1/Cip1 表达是治愈性切除食管鳞状细胞癌的预后标志物,但不是 p274Kip1、p53 或 Rb。”Ann Surg Oncol。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Osada et al.: "Prognostic significance of glutamine synthetase expression in uniforced advanced thetrullenlar carcinomal"Journal of Hepatology. 33. 247-253 (2000)
Osada 等人:“谷氨酰胺合成酶表达在单发性晚期肾癌中的预后意义”《肝脏病学杂志》。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Kitayama J, Tuno N, et al.: "Functional down-regulation of beta1 and beta2 integrins of lamina propria lymphocytes (LPL) and tumor-infiltating lymphocytes (TIL) in colorectal cancer patients."Ann Surg Oncol. 6. 500-6 (1999)
Kitayama J、Tuno N 等人:“结直肠癌患者固有层淋巴细胞 (LPL) 和肿瘤浸润淋巴细胞 (TIL) 的 β1 和 β2 整合素功能性下调。”Ann Surg Oncol。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Nagashima I, Osada T, et al.: "Histopathologic prognostic factors influencing long-term prognosis after surgical resection for hepatic metastases from colorectal cancer."Am J Gastro enterol. 94. 739-43 (1999)
Nagashima I、Osada T 等人:“影响结直肠癌肝转移手术切除术后长期预后的组织病理学预后因素。”Am J Gastro Enterol。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
共 42 条
Relationship between exercise tolerance and hemodynamic parameters in patients with peripheral vascular disease
-
批准号:19500617
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$2.75万
-
财政年份:2007
-
负责人:OSADA Takuya
-
依托单位:
Establishment of New Immunotheapy using Dendritic Cells and Evaluation of Its Inhibitory Effect on Tumor Relapse.
-
批准号:09671283
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$1.92万
-
财政年份:1997
-
负责人:OSADA Takuya
-
依托单位:
国内基金
海外基金
蛋白精氨酸甲基化转移酶PRMT5调控PPARG促进巨噬细胞M2极化及其在肿瘤中作用的机制研究
-
批准号:82371738
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:郑英霞
-
依托单位:
原发性胆汁性肝硬化(PBC)免疫生物治疗的细胞与分子机制
-
批准号:81130058
-
项目类别:重点项目
-
资助金额:260.0万元
-
批准年份:2011
-
负责人:廉哲雄
-
依托单位:
用识别EBV相关淋巴瘤抗原多肽的T细胞受体做转基因免疫治疗
-
批准号:81041002
-
项目类别:专项基金项目
-
资助金额:10.0万元
-
批准年份:2010
-
负责人:岑溪南
-
依托单位: